title: PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease.
abstract: BACKGROUND
  Huntington disease (HD) is an inherited neurodegenerative disease caused by an abnormal expansion of a CAG repeat in the huntingtin HTT (HD) gene. The primary genetic determinant of the age at onset (AO) is the length of the HTT CAG repeat; however, the remaining genetic contribution to the AO of HD has largely not been elucidated. Recent studies showed that impaired functioning of the peroxisome proliferator-activated receptor gamma coactivator 1a (PGC-1alpha) contributes to mitochondrial dysfunction and appears to play an important role in HD pathogenesis. Further genetic evidence for involvement of PGC-1alpha in HD pathogenesis was generated by the findings that sequence variations in the PPARGC1A gene encoding PGC-1alpha exert modifying effects on the AO in HD. In this study, we hypothesised that polymorphisms in PGC-1alpha downstream targets might also contribute to the variation in the AO.
  
  
  RESULTS
  In over 400 German HD patients, polymorphisms in the nuclear respiratory factor 1 gene, NRF-1, and the mitochondrial transcription factor A, encoded by TFAM showed nominally significant association with AO of HD. When combining these results with the previously described modifiers rs7665116 in PPARGC1A and C7028T in the cytochrome c oxidase subunit I (CO1, mt haplogroup H) in a multivariable model, a substantial proportion of the variation in AO can be explained by the joint effect of significant modifiers and their interactions, respectively.
  
  
  CONCLUSIONS
  These results underscore that impairment of mitochondrial function plays a critical role in the pathogenesis of HD and that upstream transcriptional activators of PGC-1alpha may be useful targets in the treatment of HD.
authors: Department of Human Genetics, Ruhr-University Bochum, Germany. larissa.arning@rub.de.
authors: Elahe
authors: E
authors: Taherzadeh-Fard
authors: Carsten
authors: C
authors: Saft
authors: Denis A
authors: DA
authors: Akkad
authors: Stefan
authors: S
authors: Wieczorek
authors: Aiden
authors: A
authors: Haghikia
authors: Andrew
authors: A
authors: Chan
authors: Jörg T
authors: JT
authors: Epplen
authors: Larissa
authors: L
authors: Arning
references: Trends Pharmacol Sci. 2009 Jun;30(6):322-9
references: 19446346
references: Hum Mol Genet. 2010 Aug 15;19(16):3190-205
references: 20529956
references: Neurogenetics. 2005 Feb;6(1):25-8
references: 15742215
references: Int J Sports Med. 2007 Sep;28(9):717-21
references: 17357964
references: Hum Mol Genet. 2009 Aug 15;18(16):3048-65
references: 19460884
references: Biochim Biophys Acta. 2002 Jun 7;1576(1-2):1-14
references: 12031478
references: Nat Genet. 1993 Aug;4(4):393-7
references: 8401588
references: J Gerontol A Biol Sci Med Sci. 2007 Sep;62(9):960-5
references: 17895433
references: Eur J Hum Genet. 2005 Aug;13(8):965-9
references: 15886711
references: J Mol Med (Berl). 2010 Apr;88(4):431-6
references: 20108082
references: Mitochondrion. 2007 Sep;7(5):354-7
references: 17660050
references: Cell. 2004 Oct 1;119(1):121-35
references: 15454086
references: J Appl Physiol (1985). 2005 Jul;99(1):344-8
references: 15705733
references: Nat Genet. 1993 Aug;4(4):387-92
references: 8401587
references: Expert Opin Ther Targets. 2007 Oct;11(10):1329-38
references: 17907962
references: Hum Mol Genet. 2008 Apr 15;17(8):1137-46
references: 18192679
references: Exp Neurol. 2010 Sep;225(1):74-84
references: 20561979
references: Fiziol Cheloveka. 2010 Mar-Apr;36(2):121-5
references: 20432700
references: Am J Clin Nutr. 2000 Aug;72(2 Suppl):512S-20S
references: 10919953
references: Neurogenetics. 2010 Oct;11(4):435-9
references: 20512606
references: Gene. 2007 Apr 15;391(1-2):198-208
references: 17300881
references: Science. 2002 Jun 21;296(5576):2225-9
references: 12029063
references: Genome Med. 2009 Aug 21;1(8):80
references: 19725930
references: Mol Neurodegener. 2011 Jan 06;6(1):1
references: 21211002
references: Nat Genet. 1993 Aug;4(4):398-403
references: 8401589
references: Mol Neurodegener. 2009 Jan 08;4:3
references: 19133136
references: Hum Genet. 2004 Apr;114(5):468-77
references: 14968360
references: Clin Chem. 2003 May;49(5):719-26
references: 12709361
references: Cell Metab. 2006 Nov;4(5):349-62
references: 17055784
references: Br J Sports Med. 2008 May;42(5):361-6
references: 18184751
references: Curr Drug Targets. 2010 Oct;11(10):1262-9
references: 20840068
references: PLoS Biol. 2005 Apr;3(4):e101
references: 15760270
references: J Mol Med (Berl). 2008 Apr;86(4):485-90
references: 18327563
references: Cell. 2006 Oct 6;127(1):59-69
references: 17018277
references: Cell. 1993 Mar 26;72(6):971-83
references: 8458085
references: Mol Neurodegener. 2009 Feb 06;4:10
references: 19200361
references: Biochim Biophys Acta. 2011 Jul;1813(7):1269-78
references: 20933024
references: J Med Genet. 2007 Jan;44(1):44-50
references: 17018562
references: J Clin Endocrinol Metab. 2007 May;92(5):1827-33
references: 17327385
references: Genes Dev. 2004 Feb 15;18(4):357-68
references: 15004004